3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
11
Ovarian Neoplasms
5
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Radiation Pneumonitis
2
Peritoneal Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophagogastric Adenocarcinoma
1
Endometrial Adenocarcinoma
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoid Tumor
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
nintedanib
×
Clear all
No trials found.